Matches in Wikidata for { <http://www.wikidata.org/entity/Q63840020> ?p ?o ?g. }
Showing items 1 to 35 of
35
with 100 items per page.
- Q63840020 description "clinical trial" @default.
- Q63840020 description "ensayu clínicu" @default.
- Q63840020 description "klinisch onderzoek" @default.
- Q63840020 description "клінічне випробування" @default.
- Q63840020 description "կլինիկական փորձարկում" @default.
- Q63840020 name "Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer" @default.
- Q63840020 type Item @default.
- Q63840020 label "Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer" @default.
- Q63840020 prefLabel "Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer" @default.
- Q63840020 P1132 Q63840020-711ED0C6-E70D-4691-81F0-1331D56E5841 @default.
- Q63840020 P1476 Q63840020-C8DE3CB7-8771-4CC9-B288-BEAB7E41F41A @default.
- Q63840020 P2899 Q63840020-D42A5DD1-FC95-45F3-A1F4-4631E5A56F06 @default.
- Q63840020 P3098 Q63840020-9A1B28C6-C752-4AEF-8A34-E53D3FA1F970 @default.
- Q63840020 P31 Q63840020-B2EFDFE8-807E-489A-BF95-F24A046D7737 @default.
- Q63840020 P580 Q63840020-D707EA28-00CC-40FC-BFF2-406B84F4098C @default.
- Q63840020 P582 Q63840020-72E343D6-D3E3-4E30-8073-BC9F1F388D14 @default.
- Q63840020 P6099 Q63840020-7E50C27B-857C-4140-A544-7552CD685DFF @default.
- Q63840020 P6153 Q63840020-362AFD14-D36A-49F7-8BA5-FF65679B9D41 @default.
- Q63840020 P6153 Q63840020-6B6D9AC3-67BA-4B2C-AE0D-12447E1BB509 @default.
- Q63840020 P6153 Q63840020-B93EA27B-F946-45F2-B033-EF2355871D72 @default.
- Q63840020 P6153 Q63840020-F8FA3575-4719-4E0E-AEB2-0B2A56A27E27 @default.
- Q63840020 P8363 Q63840020-784FA334-E6EA-40FC-9621-064D97E73B58 @default.
- Q63840020 P1132 "+118" @default.
- Q63840020 P1476 "Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer" @default.
- Q63840020 P2899 "+18" @default.
- Q63840020 P3098 "NCT01623349" @default.
- Q63840020 P31 Q30612 @default.
- Q63840020 P580 "2012-09-01T00:00:00Z" @default.
- Q63840020 P582 "2019-08-01T00:00:00Z" @default.
- Q63840020 P6099 Q5452194 @default.
- Q63840020 P6153 Q1159198 @default.
- Q63840020 P6153 Q126412 @default.
- Q63840020 P6153 Q1808012 @default.
- Q63840020 P6153 Q4897536 @default.
- Q63840020 P8363 Q78089383 @default.